Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $15.14M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
ALBEMARLE, NC 28001
ALBEMARLE, NC 28001
33aNPI1073988994assigned 12/03/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.14M
24GClaims235,450
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#37 of 92
Median peer was paid$11.47M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,650 | $1.57M | |
| 2019 | 30,769 | $1.66M | |
| 2020 | 20,331 | $1.02M | |
| 2021 | 33,788 | $2.08M | |
| 2022 | 34,399 | $2.71M | |
| 2023 | 45,854 | $3.24M | |
| 2024incomplete | 36,659 | $2.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 24,530 | 22,816 | $5.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 21,148 | 19,607 | $4.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 10,275 | 9,535 | $1.99M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.3% | 3,385 | 3,187 | $507K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 9,010 | 8,364 | $275K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 3,523 | 3,269 | $192K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 2,139 | 1,924 | $165K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 9,152 | 8,491 | $155K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,335 | 18,718 | $149K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,265 | 4,899 | $132K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,042 | 4,374 | $130K |
| 80053 | Comprehensive metabolic panel | <1% | 15,014 | 13,922 | $123K |
85 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,256 | $116K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 446 | $95K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 237 | $94K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 63 | $85K |
| J3490 | Unclassified drugs | <1% | 25,956 | $59K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,261 | $55K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 103 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 335 | $45K |
| 84484 | <1% | 5,230 | $37K | |
| 59025 | Fetal non-stress test | <1% | 556 | $36K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,522 | $36K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 137 | $35K |
| 83735 | <1% | 5,694 | $35K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,042 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,622 | $30K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,229 | $30K |
| 43235 | <1% | 194 | $29K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 137 | $27K |
| 83690 | <1% | 3,594 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,303 | $22K |
| 43450 | <1% | 224 | $21K | |
| 81025 | <1% | 2,330 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 557 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,085 | $16K |
| 83605 | <1% | 1,733 | $16K | |
| 81003 | <1% | 7,178 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,790 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 243 | $11K |
| 81001 | <1% | 2,842 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 44 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,245 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,738 | $8K |
| 87430 | <1% | 490 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,728 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,340 | $5K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 8,463 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 207 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 266 | $4K |
| 82803 | <1% | 230 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,051 | $3K |
| 64636 | <1% | 13 | $3K | |
| 87070 | <1% | 241 | $3K | |
| 64635 | <1% | 13 | $3K | |
| 83880 | <1% | 120 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 118 | $2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 26 | $2K |
| 97597 | <1% | 49 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,250 | $2K |
| 99199 | Unlisted special service, procedure or report | <1% | 255 | $1K |
| 81002 | <1% | 367 | $1K | |
| 85027 | <1% | 185 | $948.92 | |
| 80047 | <1% | 110 | $866.94 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 568 | $863.78 |
| 87081 | <1% | 99 | $639.02 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $612.05 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $612.05 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 349 | $555.91 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $554.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 25 | $492.33 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 265 | $422.88 |
| Q3014 | Telehealth originating site facility fee | <1% | 115 | $421.19 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 216 | $419.38 |
| 94761 | <1% | 24 | $389.41 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 140 | $366.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 89 | $329.58 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 89 | $328.29 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 122 | $295.58 |
| 82550 | <1% | 62 | $278.94 | |
| 82962 | <1% | 204 | $265.20 | |
| 80076 | <1% | 31 | $234.78 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 48 | $148.93 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 192 | $103.74 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 229 | $96.88 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 68 | $91.27 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 37 | $84.85 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 158 | $59.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13 | $59.15 |
| A9150 | Non-prescription drugs | <1% | 49 | $55.61 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 55 | $45.08 |
| 94760 | <1% | 13 | $29.46 | |
| 85610 | <1% | 14 | $24.50 | |
| 84100 | <1% | 12 | $23.64 | |
| A9270 | Non-covered item or service | <1% | 1,814 | $1.56 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (CFO/EXECUTIVE VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.